• 2017 April

    Obtained TFDA approval to conduct Phase III clinical studies on the treatment of ER+, HER-2- patients with late-stage breast cancer with combination of chidamide and exemestane in Taiwan.

  • 2016 November

    -Conducted research on matched pairs of chidamide in Taiwan: a retrospective study to compare OS of PTCL patients in Taiwan was conducted in three medical centers.
    -GNTbm signed a contract with Formosa Laboratories Inc. to manufacture chidamide-API in Taiwan.

  • October

    Obtained a Small Business Innovative Research award from the Small and Medium Enterprise Administration, Ministry of Economic Affairs (Project Title: Using Vaucarrin drug delivery platform to develop targeted anti-cancer drugs) (Project No:1Z1050497)

  • September

    Introduced strategic investment from investment partners; capital reached 71.88 million new Taiwan dollar.

  • July

    Applied for two PCT patents: Complex COMPRISING Metallic Nanoparticle, linkerS and ANTIBODIES and PH-SENSITIVE LINKERS FOR DELIVERING A THERAPEUTIC AGENT

  • May

    Signed a confidential agreement with international pharmaceutical companies to conduct evaluation for the international licensing of chidamide.

  • April

    Passed the new biotech company review by Industrial Development Bureau, MOEA.

  • 2015 July

    Applied for patents for the neuroprotective activity of GNT gold in the USA, EU, Japan, Taiwan, and China.

  • 2014 December

    Chidamide was approved as a Class 1.1 new drug to be used in the treatment of relapsed and refractory peripheral T cell lymphoma in China.

  • June

    Registered on Go Incubation Board for Startup and Acceleration Firms (GISA), Stock code: 7427

  • May

    Completion of issuance of common stock for cash; capital reached 55 million new Taiwan dollar.

  • April

    Obtained the Small Business Innovative Research grant awarded by the Small and Medium Enterprise Administration, Ministry of Economic Affairs (Project Title: Development of the new drug delivery platform using unique dithio-heterocyclic linkers to bind nano-gold and doxorubicin).

  • January

    Completion of internal financing; capital was increased to 45 million new Taiwan dollars

  • 2013 December

    Obtained the exclusive license to use the biomedical grade gold nanoparticles from GNT Gold Nanotech Inc. and its relevant patents.

  • October

    Renamed as GNT Biotech & Medicals Co., Ltd. with a capital of 15 million new Taiwan dollar

  • September

    Obtained an exclusive license to market the anti-cancer target drug Chidamide, developed by Chipscreen Ltd (Shenzhen, China), and its research and development in Taiwan through technology transfer.

  • August

    Officially moved into NanKang Biotech Incubation Center

  • April

    Establishment of GNT Biotech Corporation